Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 9/20 | 0.66 |
| ▸ | MAPT | P10636 | 8/20 | 0.66 |
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.66 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.66 |
| ▸ | LMNA | P02545 | 3/20 | 0.66 |
| ▸ | NPSR1 | Q6W5P4 | 3/20 | 0.66 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.66 |
| ▸ | HPGD | P15428 | 2/20 | 0.66 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.66 |
| ▸ | MEN1 | O00255 | 7/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 7/20 | 0.54 |
| ▸ | TP53 | P04637 | 1/20 | 0.51 |
| ▸ | TSHR | P16473 | 1/20 | 0.51 |
| ▸ | GRM5 | P41594 | 1/20 | 0.47 |
| ▸ | NPC1 | O15118 | 2/20 | 0.47 |
| ▸ | RAB9A | P51151 | 2/20 | 0.47 |
| ▸ | MITF | O75030 | 1/20 | 0.47 |
| ▸ | POLB | P06746 | 1/20 | 0.47 |
| ▸ | CASP6 | P55212 | 1/20 | 0.47 |
| ▸ | PAX8 | Q06710 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3922311 | 0.90 | ALDH1A1 (0.67) | ALDH1A1MAPTSMN1; SMN2KDM4ELMNA | |
| SCHEMBL14217539 | 0.86 | ALDH1A1 (0.62) | ALDH1A1MAPTSMN1; SMN2KDM4ELMNA | |
| SCHEMBL3421633 | 0.83 | ALDH1A1 (0.62) | ALDH1A1MAPTSMN1; SMN2KDM4ELMNA | |
| SCHEMBL3419640 | 0.82 | MAPT (0.79) | ALDH1A1MAPTSMN1; SMN2KDM4ELMNA | |
| SCHEMBL3423870 | 0.81 | MAPT (0.66) | ALDH1A1MAPTSMN1; SMN2KDM4ELMNA | |
| SCHEMBL3921486 | 0.79 | MAPT (0.62) | ALDH1A1MAPTSMN1; SMN2KDM4ELMNA | |
| SCHEMBL28453179 | 0.78 | STAT3 (0.68) | ALDH1A1MAPTSMN1; SMN2KDM4ELMNA | |
| SCHEMBL13739786 | 0.78 | MEN1 (0.55) | ALDH1A1MAPTSMN1; SMN2KDM4ELMNA | |
| SCHEMBL3929125 | 0.76 | ALDH1A1 (0.54) | ALDH1A1MAPTSMN1; SMN2KDM4ELMNA | |
| SCHEMBL2643572 | 0.76 | MEN1 (0.56) | ALDH1A1MAPTSMN1; SMN2KDM4ELMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090163538-A1 | Tetrahydropyridothiophenes For Use In The Treatment Of Cancer | PEKARI KLAUS | 2009-06-25 | — | — | US | disclosed |
| US-20090163538-A1 | Tetrahydropyridothiophenes For Use In The Treatment Of Cancer | PEKARI KLAUS | 2009-06-25 | — | — | US | disclosed |
| US-20090163538-A1 | Tetrahydropyridothiophenes For Use In The Treatment Of Cancer | PEKARI KLAUS | 2009-06-25 | — | — | US | disclosed |
| US-7517986-B2 | Tetrahydropyridothiophenes for use in the treatment of cancer | 4SC AG (DE) | 2009-04-14 | — | — | US | disclosed |
| US-7517986-B2 | Tetrahydropyridothiophenes for use in the treatment of cancer | 4SC AG (DE) | 2009-04-14 | — | — | US | disclosed |
| US-7517986-B2 | Tetrahydropyridothiophenes for use in the treatment of cancer | 4SC AG (DE) | 2009-04-14 | — | — | US | disclosed |
| EP-1756118-B1 | TETRAHYDROPYRIDOTHIOPHENES FOR USE IN THE TREATMENT OF CANCER | NYCOMED GMBH (DE) | 2008-05-28 | — | — | EP | disclosed |
| EP-1756118-B1 | TETRAHYDROPYRIDOTHIOPHENES FOR USE IN THE TREATMENT OF CANCER | NYCOMED GMBH (DE) | 2008-05-28 | — | — | EP | disclosed |
| US-20070213360-A1 | Tetrahydropyridothiophenes for Use in the Treatment of Cancer | NYCOMED GMBH (DE) | 2007-09-13 | — | — | US | disclosed |
| US-20070213360-A1 | Tetrahydropyridothiophenes for Use in the Treatment of Cancer | NYCOMED GMBH (DE) | 2007-09-13 | — | — | US | disclosed |
| US-20070213360-A1 | Tetrahydropyridothiophenes for Use in the Treatment of Cancer | NYCOMED GMBH (DE) | 2007-09-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090163538-A1 | Tetrahydropyridothiophenes For Use In The Treatment Of Cancer | BCL2, BAX, MCL1 | ALDH1A1 297/4885MAPT 1411/4885SMN1; SMN2 2927/4885 |
| US-20070213360-A1 | Tetrahydropyridothiophenes for Use in the Treatment of Cancer | BCL2, BAX, MCL1 | ALDH1A1 317/4885MAPT 1402/4885SMN1; SMN2 2750/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.